SMITH & NEPHEW PLC ORD USD0.20
Symbol: SN.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 28 Mar 2024 |
| Pay Date | 22 May 2024 |
| Total Dividends - Year to Date | 30.13 |
| Dividend Yield (%) | 3.0714 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 3.4357 |
| Market Cap (M) | 8593.6460 |
| Price/Earnings (PE) | 41.3924 |
| Earnings Per Share | 23.7 |
| Revenue Per Share | 5.0894 |
| Return on Equity % | 5.0210 |
1 Month Performance Chart
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy6 |
Buy5 |
Neutral6 |
Sell0 |
Strong Sell1 |
|---|---|---|---|---|---|
| Brokers | 6 | 5 | 6 | 0 | 1 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here |
0.35% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2023, Smith & Nephew plc revenues increased 6% to $5.55B. Net income increased 18% to $263M. Revenues reflect Sports Medicine & ENT segment increase of 9% to $1.73B, Orthopaedics segment increase of 5% to $2.21B, Advanced Wound Management segment increase of 6% to $1.61B, United States of America segment increase of 8% to $2.98B, Other Established Markets segment increase of 14% to $1.14B.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Revenue | 5,549.00 | 5,215.00 | 5,212.00 | 4,560.00 | 5,138.00 | 4,904.00 |
| Gross profit | 3,922.00 | 3,705.00 | 3,705.00 | 3,185.00 | 3,812.00 | 3,610.00 |
| Operating Profit/Loss | 419.00 | 442.00 | 660.00 | 295.00 | 815.00 | 863.00 |
| Profit Before Tax | 290.00 | 235.00 | 586.00 | 246.00 | 743.00 | 781.00 |
| Profit After Tax | 263.00 | 223.00 | 524.00 | 448.00 | 600.00 | 663.00 |
| Equity Holders of Parent Company | 263.00 | 223.00 | 524.00 | 448.00 | 600.00 | 663.00 |
| Minority Interest | NIL | NIL | NIL | NIL | NIL | NIL |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 5,957.00 | 6,110.00 | 6,496.00 | 6,348.00 | 6,080.00 | 4,982.00 |
| Total Current Assets | 4,030.00 | 3,856.00 | 4,424.00 | 4,664.00 | 3,219.00 | 3,077.00 |
| Total Assets | 9,987.00 | 9,966.00 | 10,920.00 | 11,012.00 | 9,299.00 | 8,059.00 |
| Total Liabilities | 4,770.00 | 4,707.00 | 5,352.00 | 5,733.00 | 4,158.00 | 3,185.00 |
| Total Net Assets | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
| Shareholders Funds | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
| Minority Interests | NIL | NIL | NIL | NIL | NIL | NIL |
| Total Equity | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy6 |
Buy5 |
Neutral6 |
Sell0 |
Strong Sell1 |
|---|---|---|---|---|---|
| Brokers | 6 | 5 | 6 | 0 | 1 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
© 2022 Refinitiv, an LSEG business. All rights reserved.
Forecasts
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | £5,831.37mn | £6,132.62mn | £6,461.89mn |
| Pre-tax-Profit | £945.21mn | £1,104.45mn | £1,186.11mn |
| EPS | £0.75p | £0.89p | £0.99p |
| EPS Growth | -9.12% | 18.27% | 11.32% |
| P/E | 12.86 | 10.88 | 9.77 |
| PEG Ratio | -1.41 | 0.60 | 0.86 |
| Dividend | 31.13p | 34.81p | 39.22p |
| Yield | 0.00% | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
| Date | Broker | Recommendation | Price | Old Target | New Target | Change |
|---|---|---|---|---|---|---|
| 18th Apr 2024 | JP Morgan Cazenove | Reiteration | 967p | 0p | 1300p | Overweight |
| 5th Apr 2024 | RBC Capital Markets | Reiteration | 975p | 0p | 1500p | Outperform |
| 3rd Apr 2024 | JP Morgan Cazenove | Reiteration | 976p | 0p | 1300p | Overweight |
| 9th Feb 2024 | Barclays | Reiteration | 1093p | 0p | 1150p | Equal-weight |
| 30th Nov 2023 | JP Morgan Cazenove | Reiteration | 1023p | 0p | 1248p | Overweight |
| 30th Nov 2023 | Berenberg Bank | Reiteration | 1023p | 0p | 1500p | Buy |
| 30th Nov 2023 | Barclays | Reiteration | 1023p | 0p | 1150p | Equal-weight |
| 6th Nov 2023 | RBC Capital Markets | Reiteration | 984p | 1600p | 1500p | Outperform |
| 2nd Oct 2023 | Barclays | Reiteration | 998p | 0p | 1200p | Underweight |
| 20th Jul 2023 | JP Morgan Cazenove | Reiteration | 1199p | 0p | 0p | Neutral |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 29 Apr 2024 | 09:35 | 982.6 | 133 | Buy |
| 29 Apr 2024 | 09:35 | 982.8 | 50 | Buy |
| 29 Apr 2024 | 09:35 | 982.8 | 43 | Buy |
| 29 Apr 2024 | 09:35 | 982.6 | 60 | Sell |
| 29 Apr 2024 | 09:35 | 983.4 | 172 | Sell |
| 29 Apr 2024 | 09:35 | 983.4 | 851 | Sell |
| 29 Apr 2024 | 09:35 | 983.2 | 202 | Sell |
| 29 Apr 2024 | 09:35 | 982.4 | 36 | Sell |
| 29 Apr 2024 | 09:34 | 983.582 | 273 | Sell |
| 29 Apr 2024 | 09:32 | 983.4 | 2 | Sell |
| 29 Apr 2024 | 09:32 | 983.4 | 12 | Sell |
| 29 Apr 2024 | 09:31 | 983.4 | 151 | Buy |
| 29 Apr 2024 | 09:31 | 983.6 | 93 | Buy |
| 29 Apr 2024 | 09:31 | 983.6 | 904 | Buy |
| 29 Apr 2024 | 09:31 | 983.6 | 253 | Buy |
| 29 Apr 2024 | 09:31 | 983.4 | 71 | Buy |
| 29 Apr 2024 | 09:31 | 983.4 | 329 | Buy |
| 29 Apr 2024 | 09:31 | 983.6 | 71 | Buy |
| 29 Apr 2024 | 09:31 | 983.6 | 400 | Buy |
| 29 Apr 2024 | 09:31 | 983.2 | 57 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.